MR4 sustained for 12 months is associated with stable deep molecular responses in chronic myeloid leukemia

oleh: Simone Claudiani, Aoife Gatenby, Richard Szydlo, George Nesr, Adi Shacham Abulafia, Renuka Palanicawandar, Georgios Nteliopoulos, Jamshid Khorashad, Letizia Foroni, Jane F. Apperley, Dragana Milojkovic

Format: Article
Diterbitkan: Ferrata Storti Foundation 2019-11-01

Deskripsi

The majority of patients with newly diagnosed chronic myeloid leukemia (CML) will enjoy a life expectancy equivalent to that of unaffected individuals, but will remain on life-long treatment with a concomitant requirement for on-going hospital interactions for molecular monitoring and drug dispensing. In order to determine more accurately the frequency of monitoring required, we performed a ‘real-life’ retrospective single-center cohort study of 450 patients with CML in at least major molecular remission (MR3) to analyze the risk of loss of MR3 [defined as at least 2 consecutive real-time quantitative polymerase chain reaction (RT-qPCR) results >0.1% International Scale (IS)]. Patients who achieved sustained MR4 (sMR4, BCR-ABL1 RT-qPCR